Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages

Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.80.

A number of analysts recently commented on the company. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Tuesday, October 8th.

Regulus Therapeutics Price Performance

Shares of RGLS stock opened at $1.50 on Tuesday. The firm has a 50-day moving average of $1.59 and a 200-day moving average of $1.89. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The company has a market cap of $98.21 million, a P/E ratio of -1.19 and a beta of 1.62.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). As a group, research analysts expect that Regulus Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Creative Planning bought a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC purchased a new stake in shares of Regulus Therapeutics during the third quarter worth $33,000. Rhumbline Advisers bought a new position in shares of Regulus Therapeutics in the second quarter worth $136,000. Tyche Wealth Partners LLC grew its position in shares of Regulus Therapeutics by 920.6% in the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 95,694 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 42,600 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.